The South America insulin infusion pump market size was valued at USD 0.19 billion in 2025 and is estimated to grow from USD 0.2 billion in 2026 to reach USD 0.26 billion by 2031, at a CAGR of 5.38% during the forecast period (2026-2031). This report is segmented by Component (Pump Devices, Infusion Sets, Reservoirs), Pump Type (Tethered, Patch, Implantable Pumps), Patient Type (Type-1, Type-2 Diabetes), End User (Hospitals & Clinics, Homecare Settings, Ambulatory Surgical Centers), and Geography (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America). Forecasts are in Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Reservoirs are forecast to be the fastest-growing component at a 6.89% CAGR during 2026-2031. Each new automated insulin delivery system creates recurring reservoir demand, while closed-loop systems adjust basal insulin and correction doses more frequently than manual therapy. This increases insulin throughput and reservoir turnover, enabling reservoir sales to grow faster than initial device placements. Brazil’s quality and biocompatibility requirements for Class III insulin-contacting components continue to favor established suppliers, although new entrants are testing incumbent pricing.
Patch pumps are forecast to grow at a 7.22% CAGR during 2026-2031 in the South America insulin infusion pump market. Their tubeless design eliminates the catheter-management burden associated with tethered systems and supports discreet use during work, sports, and daily activities. Insulet’s Omnipod has strong recognition in the regional tubeless category. Medtrum’s Nano pump received Brazilian registration in October 2025, while Uruguay’s Fondo Nacional de Recursos updated its 2025 protocol to include Nano TouchCare for eligible patients aged 2-21.
Tethered pumps retain an important installed base in Brazil and Argentina. Medtronic’s MiniMed 780G remains well established among endocrinologists treating complex type 1 diabetes, supported by expanded CE Mark indications for young children, pregnant women, and adults with insulin-requiring type 2 diabetes. These patient groups often require close clinical oversight, supporting tethered pump use in specialty practice. Chile’s March 2026 regulatory reform introduced a risk-based registration process for all pump types, with a 24-36-month transition period that may affect new device launches.
South America Insulin Infusion Pump Market Trends and Insights
Rising Type 1 Diabetes Diagnosis and Survival
Improved diagnosis rates and longer life expectancy among people with type 1 diabetes are expanding the potential user base for insulin infusion pumps in South America. Brazil had an estimated 517,290 people living with type 1 diabetes, while Argentina had 86,977 people with the condition in 2025. In Brazil, childhood type 1 diabetes incidence increased from 10.4 to 12.8 per 100,000 population between the mid-1980s and 2015. Insulin pump use reached only 3.5% in the BrazDiab1SG cohort, indicating substantial adoption potential. Expanded coverage in Argentina also supported access to pump therapy for eligible patients.Increasing Adoption of Automated Insulin Delivery
Automated insulin delivery is moving the South America insulin infusion pump market toward integrated pump-and-sensor treatment. A 2025 study of 174 users found that the share meeting all consensus glycemic targets increased from 9.7% at baseline to 52% after 12 months. In July 2025, MiniMed 780G received an expanded CE Mark indication for children aged 2 years and older, pregnant women, and adults with insulin-requiring type 2 diabetes. The United States Food and Drug Administration approved the system for insulin-requiring adults with type 2 diabetes in September 2025. Argentina had a 14% age-standardized diabetes prevalence, while Colombia had 3 million adults living with diabetes.Unequal Reimbursement and High Out-of-Pocket Costs
Unequal reimbursement coverage limited the South America insulin infusion pump market to a small share of the clinically eligible population. In Brazil, mandatory private insurance did not cover insulin pump systems or consumables, with devices costing up to BRL 30,000 (USD 5,817) and recurring consumables costing BRL 3,000 (USD 581) per month. Chile did not include pump treatment in its Garantías Explícitas en Salud benefit package, while Ley Ricarte Soto covered only 9% of eligible type 1 diabetes patients in the cited registry data. Pressure on Peru’s basic insulin supplies in early 2026 indicated continued challenges in accessing premium devices.Other drivers and restraints analyzed in the detailed report include:
- Growth of Connected Pumps and CGM Integration
- Judicialization and Individual Patient Access to High-Cost Devices
- Import Dependence, Currency Volatility, and Device Affordability
Segment Analysis
Insulin pump devices accounted for 65.12% of the South America insulin infusion pump market size in 2025, reflecting high spending on first-time hardware placements in a market with a limited installed base. Pump penetration among people with type 1 diabetes in Brazil remained below 5%. Consequently, replacement demand did not develop at the same scale as new hardware demand, supporting higher device revenue and average selling prices. Infusion sets represented the second-largest component, as clinical practice required replacement every 2-3 days.Reservoirs are forecast to be the fastest-growing component at a 6.89% CAGR during 2026-2031. Each new automated insulin delivery system creates recurring reservoir demand, while closed-loop systems adjust basal insulin and correction doses more frequently than manual therapy. This increases insulin throughput and reservoir turnover, enabling reservoir sales to grow faster than initial device placements. Brazil’s quality and biocompatibility requirements for Class III insulin-contacting components continue to favor established suppliers, although new entrants are testing incumbent pricing.
Patch pumps are forecast to grow at a 7.22% CAGR during 2026-2031 in the South America insulin infusion pump market. Their tubeless design eliminates the catheter-management burden associated with tethered systems and supports discreet use during work, sports, and daily activities. Insulet’s Omnipod has strong recognition in the regional tubeless category. Medtrum’s Nano pump received Brazilian registration in October 2025, while Uruguay’s Fondo Nacional de Recursos updated its 2025 protocol to include Nano TouchCare for eligible patients aged 2-21.
Tethered pumps retain an important installed base in Brazil and Argentina. Medtronic’s MiniMed 780G remains well established among endocrinologists treating complex type 1 diabetes, supported by expanded CE Mark indications for young children, pregnant women, and adults with insulin-requiring type 2 diabetes. These patient groups often require close clinical oversight, supporting tethered pump use in specialty practice. Chile’s March 2026 regulatory reform introduced a risk-based registration process for all pump types, with a 24-36-month transition period that may affect new device launches.
Complete Report Scope:
- By Component
- Insulin Pump Devices
- Infusion Sets
- Reservoirs
- By Pump Type
- Tethered Pumps
- Patch Pumps
- Implantable Pumps
- By Patient Type
- Type-1 Diabetes
- Type-2 Diabetes
- By End User
- Hospitals & Clinics
- Homecare Settings
- Ambulatory Surgical Centers
- By Geography
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
List of Companies Covered in this Report:
- Abbott Laboratories
- B. Braun
- Beta Bionics
- Biocon
- Dexcom
- Diabeloop SA
- Eli Lilly and Company
- Embecta Corp.
- EOFlow Co., Ltd.
- Roche
- Insulet
- Jiangsu Delfu Medical Device Co., Ltd.
- Medtronic
- Novo Nordisk
- S3 Technologies, Inc.
- Sanofi
- SOOIL Development Co., Ltd.
- Tandem Diabetes Care
- Terumo
- Ypsomed
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- B. Braun Melsungen AG
- Beta Bionics, Inc.
- Biocon Limited
- Dexcom, Inc.
- Diabeloop SA
- Eli Lilly and Company
- Embecta Corp.
- EOFlow Co., Ltd.
- F. Hoffmann-La Roche Ltd
- Insulet Corporation
- Jiangsu Delfu Medical Device Co., Ltd.
- Medtronic plc
- Novo Nordisk A/S
- S3 Technologies, Inc.
- Sanofi S.A.
- SOOIL Development Co., Ltd.
- Tandem Diabetes Care, Inc.
- Terumo Corporation
- Ypsomed Holding AG
